Advanced search
Publication Cover
Hospital Practice Volume 39, 2011 - Issue 3
Submit an article Journal homepage
67
Views
6
CrossRef citations to date
0
Altmetric
Clinical Focus: Pulmonary/Vascular Management: VTE/DVT/PE

Impact of Dyspnea on Medical Utilization and Affiliated Costs in Patients with Acute Coronary Syndrome

Machaon Bonafede Research Leader, Thomson Reuters, Washington, DCCorrespondence[email protected]
, PhD,
Yonghua Jing Associate Director, Health Services, Bristol-Myers Squibb Co., Plainsboro, NJ
, PhD,
Joette Gdovin Bergeson Director, Health Services, Bristol-Myers Squibb Co., Plainsboro, NJ
, PhD, MPA,
Danielle Liffmann Research Assistant, Thomson Reuters, Washington, DC
, BA,
Dinara Makenbaeva Associate Director, Health Services, Bristol-Myers Squibb Co., Plainsboro, NJ
, MD, MBA,
John Graham Group Director, CV/Met and Field Health Services, Bristol-Myers Squibb Co., Plainsboro, NJ
, PharmD &
Steven B. Deitelzweig Vice President of Medical Affairs, Chairman of Hospital Medicine, Ochsner Clinic Foundation, New Orleans, LA
, MD show all
Pages 16-22 | Published online: 13 Mar 2015

References

  • . Roger VL, Go AS, Lloyd-Jones DM, ; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2011 update: a report from the American Heart Association. Circulation. 2011;123(4):e18–e209
  • . Hanna EB, Glancy DL, Saucedo JF. Antiplatelet and anticoagulant therapies in acute coronary syndromes. Cardiovasc Drugs Ther. 2010;24(1):61–70
  • . Wang CS, FitzGerald JM, Schulzer M, Mak E, Ayas NT. Does this dyspneic patient in the emergency department have congestive heart failure? JAMA. 2005;294(15):1944–1956
  • . Cannon CP, Husted S, Harrington RA, ; DISPERSE-2 Investigators. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol. 2007;50(19):1844–1851
  • . Wallentin L, Becker RC, Budaj A, ; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045–1057
  • . Storey RF, Bliden KP, Patil SB, ; ONSET/OFFSET Investigators. Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study. J Am Coll Cardiol. 2010;56(3):185–193
  • . Serebruany V, Pokov I, Kuliczkowski W, Vahabi J, Atar D. Incidence and causes of new-onset dyspnea in 3,719 patients treated with clopidogrel and aspirin combination after coronary stenting. Thromb Haemost. 2008;100(2):314–318
  • . Harrison A, Morrison LK, Krishnaswamy P, . B-type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea. Ann Emerg Med. 2002;39(2):131–138
  • . Bureau of Labor Statistics; US Department of Labor. Consumer Price Index detailed report tables. Annual averages 2009. http://www.bls.gov/cpi/cpid09av.pdf. Accessed December 15, 2010
  • . Henriksson M, Nikolic E, Janzon M, Hauch O, Levin LÅ, Wallentin L, for the PLATO health economic substudy group. Long-term Costs and Health Outcomes of Treating Acute Coronary Syndrome Patients With Ticagrelor Based on the EU Label: Cost-effectiveness Analysis Based on the PLATelet Inhibition and Patient Outcomes (PLATO) Study. Presented at: 46th Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research; May 21–25, 2011; Baltimore, MD
  • . Etemad LR, McCollam PL. Total first-year costs of acute coronary syndrome in a managed care setting. J Manag Care Pharm. 2005;11(4):300–306
  • . Serebruany VL. Dyspnoea after AZD6140: safety first? Eur Heart J. 2006;27(12):1505
  • . Serebruany V, Stebbing J, Atar D. Dyspnoea after antiplatelet agents: the AZD6140 controversy. Int J Clin Pract. 2007;61(3):529–533

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.